Background and Objective: SLE is one of systemic diseases, targeting young patients, so we try to study the one of factors that affected these patients.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disorder in which organs and cells suffered from damage mediated by tissue-binding autoantibodies and immune complexes. In these patients, autoantibodies are present for years prior to the first clinical symptom (Bevra, 2013) . Early ischemic heart disease has appeared as a main cause of morbidity in SLE patients. Increased cardiovascular events can be explained by high prevalence of cardiovascular disease (CVD) risk factors such as metabolic syndrome (Rahman, 1999) . In SLE, abdominal obesity as a key-feature of metabolic syndrome with pro-inflammatory and prothrombotic state contributes to atherosclerosis (Yang, 2016) . Cytokines such as tumor necrosis factor alpha (TNF-a) are elevated in SLE and these have been linked to loss of fat-free mass (Roubenoff, 1992) . Changes in body composition have been reported in SLE patients due to the systemic inflammatory nature of the disease and prolonged corticosteroid therapy. Abnormal body composition phenotypes may represent an additional risk for CVD in SLE patients (Mok, 2008) .
Patients and Method

Study Design
Medical City, (Baghdad) and Al Fayhaa General Hospital, (Basrah) from December 2016 till June 2017. Ethical approval was taken from Medical department, College of Medicine, University of Baghdad. Participants consent was taken for inclusion in the study.
Sample Selection
A total of 60 consecutive SLE patients were involved in the study. Eligible patients included in the study were: females >18 years diagnosed to have SLE according to SLICC classification criteria for SLE (Michelle, 2012) . Exclusion criteria included: pregnancy, lactation, ischemic heart diseases, chronic kidney diseases, diabetes mellitus, overlapping inflammatory arthritis or other connective tissue disease. Another 56 -healthy volunteer women non relative to the patients who attended the hospital matched in age were participated in the study as a control group.
Clinical and Laboratory Assessment
Data collection was done using questionnaires and interview. Demographic and clinical features data included: age, sex, body mass index, smoking history, menstruation history, social class, disease duration, diseases activity, quality of life and medications used. SLE disease activity was evaluated using the SLEDAI. The disease activity scored as; no flare if <3, mild or moderate flare 3-12, and severe flare if >12 (Gladman, 2000) . Functional status (disability) was evaluated using the SLE-QoL (Systemic Lupus Erythematosus, 2017) which contain 6 domains including physical functioning, activities, symptoms, treatment, mood and self-image. The response options/scale is 7-point response scale (subsections have different anchors, including "not difficult at all" to "extremely difficult", "not at all" to "extremely troubled", and "not at all" to "extremely often") and recall period for items is 1 week. Scores range from 26-182, with higher values corresponding to worse quality-of-life. Blood and urine samples (complete blood count, C3, C4, antidsDNA, urine for protein, RBC, WBC and cast) were collected and the required tests performed in order to calculate SLE disease activity. Social grade depended on the grading system used in National Readership Survey (NRS) (Social Grade, 2017) .
Anthropometric and Body Composition: Measurements and Definitions
Standing height (in cm), and body weight (in kg) were measured, and body mass index (BMI) (kg/m (Alberti, 2015) . Body composition was measured by whole body (except head) DXA using Stratos densitometry and analyzed according to Turkish ethnicity. Fat mass index (FMI) was calculated by dividing body fat mass by the square of the height (kg/m 2 ). Appendicular Lean Mass index (ALMI) was calculated by dividing lean mass of upper and lower limbs by the square of the height (kg/m 2 ). Osteopenia is defined as total T score -1 to -2.5, while osteoporosis as total T score <-2.5 or Z score <-2 (Czerwinski, 2007) . According to the criteria recommended by Janssen et al (Ian, 2004) low skeletal muscle mass (sarcopenia) was defined as a relative appendicular lean mass index of ≤5.75 kg/m 2 in women. Normal lean body mass is 60-90% of total body weight and usually <68% consider as unhealthy.
Statistical Analysis
Normally distributed data presented using their mean and standard deviation, while non-normally distributed data presented as median and interquartile range. Binary logistic regression performed to calculate the odd ratio and it 95% confidence interval for predicting sarcopenia in SLE patients either in univariate analysis or multivariate analysis. All data analyzed using SPSS version 21, graph Pad Prism and mintab version 18. P value were considered significant if less than 0.05.
Results
The mean age of SLE patients was 31.75 ± 10.06 year and controls 34.29 ± 9.93 year. The mean BMI of SLE patients was 27.72 ± 6.98 kg/m 2 and controls 28.62 ± 5.92 kg/m 2 . There was no statistical significant differences between SLE patients and controls regarding age and BMI (p>0.05). Other demographical features between controls and SLE patients were illustrated in Table 1 . The disease characteristics of SLE patients were presented in Table 2 . The Z score was statistically significantly lower in SLE patients compared to controls, the rest of the variables showed no significant difference between SLE patients and controls as illustrated on Table 3 and Figure 1 . In univariate analysis, patients with low BMI, lower middle class, not using AZA, low LM and high FM% were associated with sarcopenia. In multivariate analysis, only the use of AZA (reduces risk of sarcopenia) and middle class and working class (reduce the risk of sarcopenia compared to unemployed class) were independent predictors of sarcopenia, the rest of the variables were dependent predictors of sarcopenia, overall the multivariate module had R2 = 0.378 which indicate it has sufficient ability to explain sarcopenia, as shown in Table 4 . AZA; azathioprine, BMD; bone mineral density, BMI; body mass index, FM; fat mass, FMI; fat mass index, LM; lean mass, PND; prednisolone, QoL; quality of life, SLEDAI; systemic lupus erythmatosus disease activity index, WC; waist circumference.
Discussion
The main finding of our study is that; central obesity, unhealthy lean mass, sarcopenia (low ALMI), and high fat mass were similar in both lupus patients and controls with no significant statistical difference (p value= 0.87, 1, 0.105, 0.61 respectively). We didn't evaluate the dietary intake, a known risk factor for altered body composition in the general population. These results are differ from study of Santos et al. (2011) which done in Caucasians population, when they found that patients with SLE and RA were likely to had abnormal body composition than noninflammatory controls. Also there is a study done by Lilleby et al. (2007) showed that body fat mass in childhood-onset SLE patients was higher and lean body mass was lower than in healthy controls. However our results are corresponding with results of Shamekhi et al. (2017) which done in Iranian population. Of course these difference reflect the social and dietary habits of different society. We found that the presence of sarcopenia in lupus patients is not affected by the disease duration nor by the disease activity, also it not affected by corticosteroid treatment (neither the dose nor the duration), however we did not assess muscle performance in our study. These findings are consisting with all above three studies, but in contrast a significant negative effect of corticosteroids on FM and LM had been reported in Kipen et al. (1998) study. On the other hand we found that sarcopenia in lupus patients was significantly more in those who had lower BMI (p value= 0.011), however low BMI is found to be dependent risk factor that means BMI itself can't predict the presence the sacropenia (BMI does not discriminate between lean and fat mass), and the sacropenia was more in patients with higher FM% (p value= 0.031). Also sacropenia was significantly more in those not treated with azathioprine (p value= 0.019). In our study, treatment with azathioprine was found to be independent protector against sarcopenia. To the best of our knowledge there is no other study showing the effect of azathioprine or other immunosuppressant on development of sarcopenia in lupus patients except for Santos et al. (2011) study who found that FM was not affected by any immunosuppressants. Lower social class across life was associated with higher fat mass in early old age and was also associated with lower lean mass in women after adjustment for fat mass as demonstrated by David Bann et al. (2014) . In our study we found a similar results. The sarcopenia was significantly reduced among patients in middle class (p value 0.003, OR 7.3 x 10 -10
) and working class (p value 0.002, OR 3.6 x 10 -10 ), while the reducing effect of lower middle class was dependent on the reduction of other risk factors. We did not study the effect of physical activity on body composition. In present study the bone density presented by total body BMD and T score was lower in lupus patients, however these lower values were insignificantly differ compared with healthy controls (p value= 0.444, 0.113 respectively). While Z score showed statistically significant lower value (p value= 0.013) among lupus patients. These results were differ from Abd El-Hady et al. (2017) study, Gilboe et al. (2000) study, and Gracanin et al. (2015) study who found that BMD, T score and Z score all were significantly lower in lupus patients. This difference also may be due to ethnic and society variations and because of bone loss in SLE is heterogeneous and likely a multifactorial process involving both traditional and lupus-related risk factors that may be due to the disease itself or due to its treatment.
In conclusion; there are no significant differences have been observed in patients' BMI, FM%, LM%, ALMI as compared with healthy individuals. Treatment with azathioprine may reduce the risk of sarcopenia and lupus patients have a high risk to loss their normal bone density.
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